肺癌脑转移病灶患者伽马刀放射治疗及全脑放射治疗的疗效  

Efficacy of Gamma Knife Radiation Therapy in Lung Cancer Patients with Brain Metastasis Lesions and Whole Brain Radiation Therapy

作　　者：刘敬聘[1] 秦坤明[1] 王仁生[1] 阮林[1] 

机构地区：[1]广西医科大学第一附属医院伽马刀科,南宁530021

出　　处：《中国医药导刊》2015年第10期978-980,共3页Chinese Journal of Medicinal Guide

摘　　要：目的：探讨分析肺癌脑转移病灶患者伽马刀放射治疗（放疗）及全脑放射治疗的疗效。方法：选取2002年3月-2013年3月在我院接受诊断和治疗的500例肺癌脑转移患者作为研究对象。根据患者具体情况决定使用伽马刀放射治疗或全脑放射治疗。伽马刀放疗组和全脑放疗组患者在性别、年龄方面差异不明显,P〉0.05,具有可比性。结果：伽马刀放疗组和全脑放疗组在近期疗效、中位生存期和1年无颅脑病灶进展生存率方面无明显差异;伽马刀放疗组的1年生存率明显高于全脑放疗组;伽马刀放疗组的不良反应率明显高于全脑放疗组。结论：使用伽马刀放疗的不良反应率较小,疗效较好,因而整体由于全脑放疗,但是在临床实践中也应该考虑患者具体情况而决定治疗方案,对于肿瘤较大的患者可以将二者结合以取得更为满意的疗效。Objective： To investigate the efficacy analysis of lung lesions in patients with brain metastases Gamma Knife radiation therapy and whole brain radiation therapy.Methods：March 2002 - March 2013 in our hospital diagnosis and treatment of 500 cases of lung cancer patients with brain metastases as the research object. According to the specific circumstances of the patient decided to use the gamma knife radiation therapy or whole brain radiation therapy.Gamma Knife radiotherapy group and whole brain radiotherapy group in gender, age was not significantly different,P〉0.05,comparable.Results：The Gamma Knife radiotherapy group and whole brain radiotherapy efficacy in the near future, with a median survival time and 1-year progression-free survival without brain lesions was no significant difference; 1-year survival rate was significantly higher than the gamma knife radiotherapy whole brain radiotherapy; adverse reaction rate of gamma knife radiotherapy group was significantly higher than the whole-brain radiotherapy. Conclusion： The adverse reaction rates using the gamma knife radiation is small, good effect, and thus overall due to the whole brain radiotherapy, but in clinical practice should also consider the specific circumstances of the patient treatment decisions for patients with larger tumors may be two were combined to achieve a more satisfactory outcome.

关 键 词：肺癌脑转移 伽马刀放射治疗 全脑放射治疗 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤] R815[医药卫生—临床医学]